<p class="title">Drug major Glenmark Pharma on Tuesday said it has received final approval from the US health regulator for Clobetasol Propionate Foam, indicated for the treatment of plaque psoriasis.</p>.<p class="bodytext">The approved product is a generic version of Olux-E Foam, 0.05 per cent, of Mylan Pharmaceuticals.</p>.<p class="bodytext">"Glenmark Pharmaceuticals, USA, has been granted final approval by the United States Food and Drug Administration (USFDA) for Clobetasol Propionate Foam, 0.05 per cent (emulsion formulation)," Glenmark said in a regulatory filing.</p>.<p class="bodytext">Quoting to IQVIA sales data for the 12 month period ending July 2019, Glenmark said the Olux-E Foam, 0.05 per cent, market achieved annual sales of approximately USD 11.1 million.</p>.<p class="bodytext">Glenmark said current portfolio consists of 161 products authorised for distribution in the US marketplace and 54 abbreviated new drug applications are pending approval with the USFDA.</p>
<p class="title">Drug major Glenmark Pharma on Tuesday said it has received final approval from the US health regulator for Clobetasol Propionate Foam, indicated for the treatment of plaque psoriasis.</p>.<p class="bodytext">The approved product is a generic version of Olux-E Foam, 0.05 per cent, of Mylan Pharmaceuticals.</p>.<p class="bodytext">"Glenmark Pharmaceuticals, USA, has been granted final approval by the United States Food and Drug Administration (USFDA) for Clobetasol Propionate Foam, 0.05 per cent (emulsion formulation)," Glenmark said in a regulatory filing.</p>.<p class="bodytext">Quoting to IQVIA sales data for the 12 month period ending July 2019, Glenmark said the Olux-E Foam, 0.05 per cent, market achieved annual sales of approximately USD 11.1 million.</p>.<p class="bodytext">Glenmark said current portfolio consists of 161 products authorised for distribution in the US marketplace and 54 abbreviated new drug applications are pending approval with the USFDA.</p>